CancerNetwork Members: Login | Register
Become a fan on Facebook  Add us on Google Plus Follow us on Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 


 
CONNECT WITH US
Become a fan on
Facebook
Add us on
Google Plus
Follow us on
Twitter
Join us on
LinkedIn
Sign up for our
Newsletters
Subscribe to our
RSS Feed

Bone Metastases

 
 
FEATURED CONTENT

Denosumab, a RANK Ligand Inhibitor for Prevention of Skeletal-Related Events Due to Bone Metastases From Solid Tumors in Adults
Gail M. Wilkes, MS, APRN-BC, AOCN , April 18, 2011

Denosumab is an IgG2 monoclonal antibody that inhibits osteoclastic bone resorption (breakdown) via inhibition of RANKL (receptor activator of nuclear factor-kB ligand).

Revised Guidelines on Metastatic Breast Cancer Bone Metastases
Anna Azvolinsky, PhD , March 21, 2011

The American Society of Clinical Oncology (ASCO) updated its recommendation last month on the role of bone-modifying agents in the prevention of skeletal-related events (SREs) for metastatic breast cancer patients with bone metastases.

ASTRO Publishes Guidelines for Palliative Radiotherapy for Bone Metastases
CancerNetwork Editors , February 18, 2011

The American Society for Radiation Oncology (ASTRO) has released guidelines for the use of radiation therapy in treating bone metastases; the guidelines will be published in the International Journal of Radiation Oncology, Biology, Physics.

Denosumab Continues to Dampen Skeletal-Related Side Effects in Breast Cancer Bone Metastases
By John Schieszer , December 13, 2010

An update of a long-term denosumab (Xgeva) trial offers another bisphosphonate as an alternative to zoledronic acid (Zometa) that is more convenient, less toxic, and more effective in bone metastases. But oncologists need to perform an oral exam of patients with bone metastases before placing them on denosumab.

Industry Update: Agents Slow Disease Progression, Improve Daily Function in Metastatic Breast Cancer
Shalmali Pal , December 10, 2010

Results from the GINECO group study demonstrate Afinitor’s ability to buy more time for patients while Xgeva makes everyday life less painful.

ASTRO guideline sets standard for use of radiotherapy as palliative treatment of pain from bone metastases
September 1, 2010

Stephen Lutz, MD, talks about the evolution of the ASTRO guideline and how it answers vital questions for radiation oncologists.

A Look at Novel Approaches in Bone Mets
August 13, 2010

Although the use of bisphosphonates is a well-established form of supportive care treatment for bone metastasis, complications arising from long-term use require schedule optimization and a search for alternative strategies.

Bisphosphonates and RANK Ligand Inhibitors for Metastatic Bone Disease
August 13, 2010

Early data from an ongoing randomized trials in the UK strongly suggest that denosumab might play a defined role in the future management of metastatic bone disease.

Combo Treatment Looks Promising
August 13, 2010

Complications of the bone remain a major clinical problem in oncology, resulting in significant morbidity and increased risk of death.

Whole-body MRI finds breast cancer metastases earlier
May 17, 2010

Whole-body MRI should be the go-to imaging modality for detecting bone metastases in asymptomatic patients.

Showing 11 - 20 of 34 results.
Page of 4
First Last
 
MEDLINE
Local bone marrow renin-angiotensin system in primitive, definitive and neoplastic haematopoiesis.
pubmed.gov - 2/28/13
The locally active ligand peptides, mediators, receptors and signalling pathways of the haematopoietic BM (bone marrow) autocrine/paracrine RAS (renin-angiotensin system) affect the essential steps of definitive blood cell production. Haematopoiesis, erythropoiesis, myelopoiesis, formation of monocytic and lymphocytic lineages, thrombopoiesis and other stromal cellular elements are regulated by the local BM RAS. The local BM RAS is present and active even in primitive embryonic haematopoiesis. ACE (angiotensin-converting enzyme) is expressed on the surface of the first endothelial and haematopoietic cells, forming the marrow cavity in the embryo. ACE marks early haematopoietic precursor cells and long-term blood-forming CD34(+) BM cells. The local autocrine tissue BM RAS may also be active in neoplastic haematopoiesis. Critical RAS mediators such as renin, ACE, AngII (angiotensin II) and angiotensinogen have been identified in leukaemic blast cells. The local tissue RAS influences
Stroma-directed imatinib therapy impairs the tumor-promoting effect of bone marrow-derived mesenchymal stem cells in an orthotopic transplantation model of colon cancer.
pubmed.gov - 2/14/13
Bone marrow-derived mesenchymal stem cells (MSCs) are reported to contribute to formation of tumor-promoting stromal cells. We reported recently that, in an orthotopic nude mice model of colon cancer, MSCs traveled to tumor stroma, where they differentiated into carcinoma-associated fibroblast (CAF)-like cells. We also found that CAFs express platelet-derived growth factor receptor (PDGFR) at a high level and that imatinib therapy targeting PDGFR in CAFs inhibits growth and metastasis of human colon cancer. These findings led us to examine whether the tumor-promoting effect of MSCs is impaired by blockade of PDGFR signaling achieved with imatinib. Orthotopic transplantation and splenic injection of human MSCs along with KM12SM human colon cancer cells, in comparison with transplantation of KM12SM cells alone, resulted in significantly greater promotion of tumor growth and liver metastasis. The KM12SM + MSC xenograft enhanced cell proliferation and angiogenesis and inhibited tumor cell
Targeted radio-nuclide therapy of skeletal metastases.
pubmed.gov - 1/31/13
In this review, we will focus on one particular class of stromal targeted therapy, i.e. the bone seeking radiopharmaceuticals (BSRs), but will also highlight selected issues related to the bone stroma as these concepts are new, rapidly evolving, and clearly linked to the underlying BSR mechanisms of targeting and action. Herein we review clinical BSR-trials of significance with randomized trials at center stage. Furthermore, we cover a new class of BSR in late clinical development based on bone-stromal targeted alpha-particle irradiation. Lastly, we discuss potential advances in combining BSR with bisphosphonates and/or chemotherapy and emphasize the feasibility of repeated dosing.
Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis.
pubmed.gov - 1/31/13
We conducted a systematic review of the literature to determine the efficacy and safety of denosumab in reducing skeletal-related events (SRE) in patients with bone metastases.|A literature search using MEDLINE, EMBASE, Web of Science and The Cochrane Collaboration Library identified relevant controlled clinical trials up-to-March 14, 2012. Two independent reviewers assessed studies for inclusion, according to predetermined criteria, and extracted relevant data. The primary outcomes of interest were SRE, time to first on-study SRE, and overall survival. Secondary outcomes included pain, quality of life, bone turnover markers (BTM), and adverse events.|Six controlled trials including 6142 patients were analyzed. Compared to zoledronic acid, denosumab had lower incidence of SRE with a risk ratio (RR) of 0.84 (95% confidence intervals (CI) 0.80-0.88), delayed the onset of first on-study SRE (RR 0.83; 95% CI 0.75-0.90) and time to worsening of pain (RR 0.84; 95% CI 0.77-0.91). No
Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients.
pubmed.gov - 1/14/13
In the recent years, fluorine 18 fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET)/computed tomography (CT) has emerged as a new modality for staging non-small-cell lung cancer (NSCLC) patients. The aim of this meta-analysis was to assess the diagnostic value of (18)F-FDG PET/CT in detecting metastatic lesions in NSCLC patients. Meta-analysis methods were used to pool sensitivity, specificity, positive and negative likehood ratios, diagnostic odd ratios and to construct a summary receiver-operating characteristic curve. Data from included studies were pooled to compare the diagnostic accuracy between PET/CT and PET or CT alone in nodal staging. Totally, 56 studies involving 8,699 patients met the inclusion criteria. The pooled sensitivities and specificities of (18)F-FDG PET/CT were 0.72 [95% confidence interval (CI): 0.65-0.78] and 0.91 (95% CI: 0.86-0.94) in determining mediastinal nodal staging; 0.71 (95% CI: 0.60-0.80) and 0.83 (95% CI: 0.77-0.88) in intrathoracic

Result Pages: 1 2 3 4 5 6 Next


 
CLINICAL TRIALS
LAB-IMMUNOLOGY RESEARCH
neuro-oncology.oxfordjournals.org - 11/4/12
Zoledronate in Preventing Skeletal (Bone)-Related Events in Patients Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases
www.clinicaltrials.gov -
Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone Therapy
www.clinicaltrials.gov -
Effect of Androgen Suppression on Bone Loss in Patients With or Without Bone Metastases Secondary to Prostate Cancer
www.clinicaltrials.gov -
Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases
www.clinicaltrials.gov -

Result Pages: 1 2 3 4 5 6 Next



 
IMAGE IQ

Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
James B. Yu, MD1 , May 17, 2013

A 70-year-old man with a history of localized prostate cancer treated with whole-pelvis radiation therapy with a boost to the prostate, in conjunction with androgen deprivation therapy 7 years prior, presented with lower back pain. A bone scan revealed an area of activity in the sacrum. What is the most likely diagnosis?


 
   SEARCH MEDICA RX
   Browse drugs by name:
A B C D E F G H I J
K L M N O P Q R S T
U V W X Y Z All      
   Search for drugs:
Search

 
 
FROM PHYSICIANS PRACTICE
Five Steps to Improving Patient Access
Judy Capko,  May 21, 2013
Patient access is getting increased attention through reform initiatives. Here are five steps you can take to make sure patients get appropriate access to care in your office.
Growing HIPAA Threat – Ignore Windows XP at Your Own Peril
Marion K. Jenkins,  May 21, 2013
Chances are good that you have some major ticking software time bombs lurking in your medical practice's computer environment, namely Windows XP and Server 2003.
Finding Physician Work-Life Balance in the Small Moments
Jennifer Frank, MD,  May 21, 2013
At my practice and at home, things are always busy. There's laundry or homework, or a patient with needs.
Three Areas to Reduce Costs at Your Medical Practice
Greg Mertz,  May 19, 2013
By taking a hard look at reducing costs for staffing, overhead, and technology at your medical practice, you may see increased physician compensation.
Dos and Don’ts for Starting a Physician Blog
Michael Woo-Ming, MD,  May 18, 2013
Starting a physician blog can provide your medical practice with marketing benefits, but it's important to do it right.
 

 
 
COMMENTS